Samjin Pharmaceutical and Huray Positive Sign Business Agreement... Strengthening Digital Healthcare Business

[Asia Economy Reporter Lee Gwan-joo] Samjin Pharmaceutical announced on the 30th that it has signed a memorandum of understanding (MOU) with 'Hurey Positive' to promote cooperation in the digital healthcare business sector.

The two companies agreed to jointly explore and promote new businesses in the digital healthcare field, including establishing a business model for digital therapeutics linked to Samjin Pharmaceutical's existing pharmaceutical business, planning detailed execution plans, and mutual cooperation in the digital healthcare business sector promoted by Hurey Positive.

Samjin Pharmaceutical plans to actively foster future growth engines through this agreement. In particular, it aims to strengthen its related portfolio by establishing 'digital therapeutics,' a recent hot topic in the healthcare market, as a new business model linked to its existing pharmaceutical business.

Choi Doo-ah, CEO of Hurey Positive, said, "Through this business partnership, we will establish a specialized business model with Samjin Pharmaceutical by combining existing pharmaceuticals with the latest digital therapeutic protocols, and cooperate so that customers can pursue health more efficiently and effectively through digital healthcare."

Previously, in 2020, Samjin Pharmaceutical declared its entry into the digital healthcare market by signing a business cooperation and investment agreement with Wellisys, a spin-off company of Samsung SDS, and is currently conducting domestic business for the patch-type digital electrocardiogram analysis solution 'S-Patch Ex,' equipped with AI interpretation technology for rapid and accurate diagnosis and management of arrhythmia symptoms.

Additionally, based on strengths secured in the cardiovascular drug market through the antithrombotic agent 'Pleris' and the anticoagulant 'Riboxaban,' launched last year, the company is striving to create synergy with the digital healthcare market. Choi Yong-joo, CEO of Samjin Pharmaceutical, emphasized, "This agreement has provided an opportunity to strengthen cooperation between the rapidly growing digital healthcare market and the existing pharmaceutical business," adding, "We will take a further step forward as a company that provides integrated solutions covering the entire treatment service for medical professionals and patients."

This content was produced with the assistance of AI translation services.